BCL2 and B-cell chronic lymphocytic leukemia: Pathway inhibitors (PI) such as BTK-inhibitors (BTKi), PI3-Kinase inhibitors (PI3Ki), and BCL2-inhibitors (BCL2i) have fundamentally transformed the standard treatment landscape for chronic lymphocytic leukemia (CLL) in recent years.